Clicky

Alvotech(ALVO)

Description: Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.


Keywords: Medicine Cancer Clinical Medicine Surgery Radiation Autoimmune Disease Monoclonal Antibodies Rheumatoid Arthritis Ulcerative Colitis Crohn's Disease Diabetic Retinopathy Psoriatic Arthritis Immunosuppressants Macular Edema Plaque Psoriasis Age Related Macular Degeneration Inflammatory Conditions Tnf Inhibitors Adalimumab Biosimilar Products Humira Bone Disorders Nasal Polyps Eylea Stelara Xgeva

Home Page: www.alvotech.com

Saemundargata 15-19
Reykjavik, 102
Iceland
Phone: 354 422 4500


Officers

Name Title
Mr. Robert Wessman Founder & Exec. Chairman of Directors
Mr. Mark Levick Chief Exec. Officer
Mr. Joel Morales Chief Financial Officer
Mr. Sean Gaskell Chief Technical Officer
Mr. Joseph E. McClellan Chief Scientific Officer
Ms. Rose-Marie Ohlsson Chief Information Officer
Ms. Sigridur Elin Gudlaugsdottir VP of HR
Ms. Tanya Zharov Deputy Chief Exec. Officer
Mr. Anil Okay Chief Commercial Officer
Mr. Ming Li Chief Strategy Officer

Exchange: IC

Country: IS

Currency: Icelandik Krona (kr)

Forward PE: 0
Trailing PE: 49.4227
Price-to-Book MRQ: 0
Price-to-Sales TTM: 3038.308
IPO Date:
Fiscal Year End: December
Full Time Employees: 784
Back to stocks